These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 17855108

  • 1. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?
    Diel IJ, Fogelman I, Al-Nawas B, Hoffmeister B, Migliorati C, Gligorov J, Väänänen K, Pylkkänen L, Pecherstorfer M, Aapro MS.
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):198-207. PubMed ID: 17855108
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE, Umland EM.
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [Abstract] [Full Text] [Related]

  • 6. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
    Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, Riedel ER, Carlson DL, Schoder H, Farooki A, Fornier M, Halpern JL, Tunick SJ, Huryn JM.
    Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
    [Abstract] [Full Text] [Related]

  • 7. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
    Dickinson M, Prince HM, Kirsa S, Zannettino A, Gibbs SD, Mileshkin L, O'Grady J, Seymour JF, Szer J, Horvath N, Joshua DE.
    Intern Med J; 2009 May; 39(5):304-16. PubMed ID: 19220531
    [Abstract] [Full Text] [Related]

  • 8. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [Abstract] [Full Text] [Related]

  • 9. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R, Need A, Hughes T, Goss A.
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [Abstract] [Full Text] [Related]

  • 10. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid.
    García Sáenz JA, López Tarruella S, García Paredes B, Rodríguez Lajusticia L, Villalobos L, Díaz Rubio E.
    Med Oral Patol Oral Cir Bucal; 2007 Sep 01; 12(5):E351-6. PubMed ID: 17767097
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bisphosphonate-related osteonecrosis of the jaw in cancer patients: Implications for nurses.
    Morris M, Cruickshank S.
    Eur J Oncol Nurs; 2010 Jul 01; 14(3):205-10. PubMed ID: 20129822
    [Abstract] [Full Text] [Related]

  • 13. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review.
    Silverman SL, Landesberg R.
    Am J Med; 2009 Feb 01; 122(2 Suppl):S33-45. PubMed ID: 19187811
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P.
    Breast Cancer Res Treat; 2010 Jul 01; 122(1):181-8. PubMed ID: 20361252
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment.
    Fehm T, Felsenberg D, Krimmel M, Solomayer E, Wallwiener D, Hadjii P.
    Breast; 2009 Aug 01; 18(4):213-7. PubMed ID: 19651512
    [Abstract] [Full Text] [Related]

  • 16. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF.
    Ann N Y Acad Sci; 2011 Feb 01; 1218():47-54. PubMed ID: 20946574
    [Abstract] [Full Text] [Related]

  • 17. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T, Cheng A, Stein B, Goss A.
    J Oral Maxillofac Surg; 2007 Mar 01; 65(3):415-23. PubMed ID: 17307586
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management.
    Ruggiero SL, Mehrotra B.
    Annu Rev Med; 2009 Mar 01; 60():85-96. PubMed ID: 18928335
    [Abstract] [Full Text] [Related]

  • 19. [Osteonecrosis of the jaw and bisphophonates in oncology].
    Facon T, Bensadoun RJ, Blanc JL, Confavreux C, Gourmet R, Maes JM, Penel G, Vieillard MH, Woeller A.
    Bull Cancer; 2008 Apr 01; 95(4):413-8. PubMed ID: 18495570
    [Abstract] [Full Text] [Related]

  • 20. Safety profile of intravenous bisphosphonates.
    Mehrotra B.
    Semin Oncol; 2007 Dec 01; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.